Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Telix Pharmaceuticals Ltd Director's Dealing 2017

Nov 14, 2017

31324_rns_2017-11-14_30cde982-2c6f-46f6-ba6d-939fb45580dc.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Harry Kevin McCann
Date of appointment 17 September 2017

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Not applicable

  • See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of
interest
Note: Provide details of the circumstances giving rise to
the relevant interest.
Monjoy Pty Limited Family Trust AC> of which Harry
Kevin McCann is a director of the
Trustee.
Cottesloe Pty Limited of which
Harry Kevin McCann is a director
and substantial shareholder.
Number & class of Securities
160,000 fully paid ordinary shares, acquired in
the Initial Public Offering of the Company at a
price of $0.65 per share.
990,000 unlisted share options with an exercise
price of $0.85 per option and an expiry date of
14 October 2021, granted subsequent to
shareholder approval at the EGM held 13
October 2017.

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
No. and class of securities to which
interest relates
  • See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002